Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting mitochondrial impairment for the treatment of cardiovascular diseases: From hypertension to ischemia-reperfusion injury, searching for new pharmacological targets.
Todisco S, Musio B, Pesce V, Cavalluzzi MM, Petrosillo G, La Piana G, Sgobba MN, Schlosserová N, Cafferati Beltrame L, Di Lorenzo R, Tragni V, Marzulli D, Guerra L, De Grassi A, Gallo V, Volpicella M, Palese LL, Lentini G, Pierri CL. Todisco S, et al. Among authors: volpicella m. Biochem Pharmacol. 2023 Feb;208:115405. doi: 10.1016/j.bcp.2022.115405. Epub 2023 Jan 2. Biochem Pharmacol. 2023. PMID: 36603686 Review.
Mitochondria as pharmacological targets in Down syndrome.
Valenti D, Braidy N, De Rasmo D, Signorile A, Rossi L, Atanasov AG, Volpicella M, Henrion-Caude A, Nabavi SM, Vacca RA. Valenti D, et al. Among authors: volpicella m. Free Radic Biol Med. 2018 Jan;114:69-83. doi: 10.1016/j.freeradbiomed.2017.08.014. Epub 2017 Aug 31. Free Radic Biol Med. 2018. PMID: 28838841 Review.
Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
Tragni V, Preziusi F, Laera L, Onofrio A, Mercurio I, Todisco S, Volpicella M, De Grassi A, Pierri CL. Tragni V, et al. Among authors: volpicella m. EPMA J. 2022 Jan 6;13(1):149-175. doi: 10.1007/s13167-021-00267-w. eCollection 2022 Mar. EPMA J. 2022. PMID: 35013687 Free PMC article.
Personalized Medicine in Mitochondrial Health and Disease: Molecular Basis of Therapeutic Approaches Based on Nutritional Supplements and Their Analogs.
Tragni V, Primiano G, Tummolo A, Cafferati Beltrame L, La Piana G, Sgobba MN, Cavalluzzi MM, Paterno G, Gorgoglione R, Volpicella M, Guerra L, Marzulli D, Servidei S, De Grassi A, Petrosillo G, Lentini G, Pierri CL. Tragni V, et al. Among authors: volpicella m. Molecules. 2022 May 29;27(11):3494. doi: 10.3390/molecules27113494. Molecules. 2022. PMID: 35684429 Free PMC article. Review.
BRAFV600E;K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy.
Porcelli L, Di Fonte R, Pierri CL, Fucci L, Saponaro C, Armenio A, Serratì S, Strippoli S, Fasano R, Volpicella M, Daprile R, Tommasi S, Ressa CM, Guida M, Azzariti A. Porcelli L, et al. Among authors: volpicella m. Pharmacol Res. 2022 Aug;182:106323. doi: 10.1016/j.phrs.2022.106323. Epub 2022 Jun 22. Pharmacol Res. 2022. PMID: 35752358 Free article.
Down syndrome: Neurobiological alterations and therapeutic targets.
Vacca RA, Bawari S, Valenti D, Tewari D, Nabavi SF, Shirooie S, Sah AN, Volpicella M, Braidy N, Nabavi SM. Vacca RA, et al. Among authors: volpicella m. Neurosci Biobehav Rev. 2019 Mar;98:234-255. doi: 10.1016/j.neubiorev.2019.01.001. Epub 2019 Jan 4. Neurosci Biobehav Rev. 2019. PMID: 30615933 Review.
48 results